title: Acceptability of Carraguard vaginal gel use among Thai couples.
abstract: OBJECTIVE
  To evaluate the acceptability of candidate microbicide Carraguard among couples participating in a safety trial.
  
  
  METHODS
  A 6-month randomized, placebo-controlled trial was conducted in sexually active, low-risk couples in Thailand.
  
  
  METHODS
  Couples who were monogamous, HIV uninfected, and not regular condom users were enrolled. Acceptability data were collected through structured questionnaires at repeated intervals. At the closing study visit, participants were asked questions about hypothetical product characteristics and future use. Compliance with gel use was assessed by questionnaires, coital diaries, and tracking of used and unused applicators.
  
  
  RESULTS
  Among 55 enrolled couples, follow up and adherence with gel use were high and sustained, with 80% of women using gel in over 95% of vaginal sex acts. Because acceptability results from Carraguard and placebo arms were similar, they were combined for this analysis. Overall, 92% of women and 83% of men liked the gel somewhat or very much; 66% of women and 72% of men reported increased sexual pleasure with gel use; and 55% of women and 62% of men reported increased frequency of intercourse. Only 15% of women but 43% of men thought that gel could be used without the man knowing. Although men and women had similar views overall, concordance within couples was low, with no kappa coefficients above 0.31.
  
  
  CONCLUSIONS
  Carraguard gel use was acceptable to low-risk couples in northern Thailand. Reported associations between gel use and increased sexual pleasure and frequency suggest a potential to market microbicide products for both disease prevention and enhancement of pleasure.
authors.affiliation: National Center for HIV, Viral Hepatitis, STDs, and Tuberculosis Prevention (proposed), Centers for Disease Control and Prevention, Atlanta, USA. svw7@cdc.gov
authors.forename: Sara J
authors.initials: SJ
authors.lastname: Whitehead
authors.forename: Peter H
authors.initials: PH
authors.lastname: Kilmarx
authors.forename: Kelly
authors.initials: K
authors.lastname: Blanchard
authors.forename: Chomnad
authors.initials: C
authors.lastname: Manopaiboon
authors.forename: Supaporn
authors.initials: S
authors.lastname: Chaikummao
authors.forename: Barbara
authors.initials: B
authors.lastname: Friedland
authors.forename: Jullapong
authors.initials: J
authors.lastname: Achalapong
authors.forename: Mayuree
authors.initials: M
authors.lastname: Wankrairoj
authors.forename: Philip
authors.initials: P
authors.lastname: Mock
authors.forename: Sombat
authors.initials: S
authors.lastname: Thanprasertsuk
authors.forename: Jordan W
authors.initials: JW
authors.lastname: Tappero
mesh_terms: D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D002351:Carrageenan / Q000008:administration & dosage*; D005260:Female; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D008297:Male; D010349:Patient Compliance; D017060:Patient Satisfaction; D012747:Sexual Partners; D014227:Triazines / Q000008:administration & dosage*; D014622:Vaginal Creams, Foams, and Jellies
chemical_list: D000890:Anti-Infective Agents; D014227:Triazines; D014622:Vaginal Creams, Foams, and Jellies; C013431:caragard; D002351:Carrageenan